We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+41.47%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$4.2B
AUM Growth
+$1.6B
Cap. Flow
+$825M
Cap. Flow %
19.63%
Top 10 Hldgs %
44.15%
Holding
117
New
24
Increased
10
Reduced
49
Closed
12

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$207M
2
OLMA icon
Olema Pharmaceuticals
OLMA
+$150M
3
BCAB icon
BioAtla
BCAB
+$76.6M
4
CCCC icon
C4 Therapeutics
CCCC
+$72.2M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$48.8M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$61.3M
2
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
+$50.2M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$35.5M
4
TWST icon
Twist Bioscience
TWST
+$30.5M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$30M

Sector Composition

Rank Sector Weight
1 Healthcare 78.9%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTNT
76
DELISTED
Quotient Limited Ordinary Shares
QTNT
$7.82M 0.19%
37,500
-12,500
-25% -$2.91M
ALLK
77
DELISTED
Allakos
ALLK
$7M 0.17%
50,000
-25,000
-33% -$2.6M
PNT
78
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$6.97M 0.17%
500,000
– –
MORF
79
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$6.71M 0.16%
200,000
-50,000
-20% -$1.48M
MRUS
80
DELISTED
Merus
MRUS
$6.14M 0.15%
350,000
-79,284
-18% -$1.17M
GTH
81
DELISTED
Genetron Holdings Limited ADS
GTH
$5.6M 0.13%
133,333
-33,334
-20% -$1.21M
BLSA
82
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$5.51M 0.13%
+500,000
New +$5.36M
FSDC
83
DELISTED
FS Development Corp. Class A Common Stock
FSDC
$5.5M 0.13%
500,000
– –
FVAM
84
DELISTED
5:01 Acquisition Corp
FVAM
$5.08M 0.12%
+500,000
New +$5.05M
EIGR
85
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.92M 0.12%
13,333
-1,651
-11% -$474K
VSPRU
86
DELISTED
Vesper Healthcare Acquisition Corp. Unit
VSPRU
$4.85M 0.12%
400,000
– –
REPL icon
87
Replimune Group
REPL
$1.01B
$4.77M 0.11%
+125,000
New +$5.21M
MLTX icon
88
MoonLake Immunotherapeutics
MLTX
$1.55B
$4.74M 0.11%
+430,000
New +$4.57M
BCEL
89
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$4.74M 0.11%
293,500
– –
AUTL
90
Autolus Therapeutics
AUTL
$562M
$3.77M 0.09%
422,167
– –
KDMN
91
DELISTED
Kadmon Holdings, Inc.
KDMN
$3.53M 0.08%
850,000
-150,000
-15% -$592K
TECX
92
Tectonic Therapeutic
TECX
$606M
$3.4M 0.08%
20,336
– –
PANA.U
93
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$3.19M 0.08%
250,000
– –
TCDA
94
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.02M 0.07%
427,975
-300,000
-41% -$2.3M
DTIL icon
95
Precision BioSciences
DTIL
$207M
$2.89M 0.07%
11,551
– –
CRDF icon
96
Cardiff Oncology
CRDF
$77.2M
$2.7M 0.06%
150,000
-25,000
-14% -$439K
ARNA
97
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.54M 0.04%
20,000
-10,000
-33% -$750K
VRDN icon
98
Viridian Therapeutics
VRDN
$2.67B
$1.53M 0.04%
+93,126
New +$1.4M
ORTX
99
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.11M 0.03%
25,665
– –
FATE icon
100
Fate Therapeutics
FATE
$326M
$909K 0.02%
10,000
-5,000
-33% -$310K
1 2 3
4
5

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2020 Portfolio in Review

As of Q4 2020, Cormorant Asset Management held 117 positions worth $4.2B, up 62% from $2.6B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $825M of net new capital in Q4 2020, opening 24 new positions and adding to 10 existing holdings. Its largest new stake was Atea Pharmaceuticals: 6,411,355 shares worth $260M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 80% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Twist Bioscience, an estimated $30.5M trimmed.

  • Cormorant Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 6,411,355 shares worth $260M.
  • Cormorant Asset Management added most to Forma Therapeutics Holdings, Inc. Common Stock in Q4 2020, an estimated $47M increase.
  • Cormorant Asset Management's biggest Q4 2020 reduction was Twist Bioscience, cutting an estimated $30.5M.
  • Cormorant Asset Management fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $61.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $4.2B portfolio in Q4 2020.
  • Cormorant Asset Management opened 24 new positions and closed 12 in Q4 2020.
  • Cormorant Asset Management's portfolio value rose 62% quarter-over-quarter to $4.2B.

Based on Cormorant Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.